Drug profile · INN
ritlecitinib tosylate
LITFULO
ritlecitinib tosylate (LITFULO) is a tec family kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ritlecitinib tosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ritlecitinib tosylate (LITFULO) is a tec family kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
TEC family kinase inhibitor
Primary target: TEC family kinase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ritlecitinib tosylate?
ritlecitinib tosylate (LITFULO) is a tec family kinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ritlecitinib tosylate?
LITFULO is a marketed brand name for ritlecitinib tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ritlecitinib tosylate?
ritlecitinib tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.